ASCO Genitourinary Cancers Symposium
ASCO GU 2022 on Nivo + Cabo vs. Sunitinib for Advanced RCC: Final OS Analysis and Organ-Specific Target Lesion Assessments w/ 2-Year Follow-Up in CheckMate 9ER
By
ASCO Genitourinary Cancers Symposium
FEATURING
Thomas Powles
By
ASCO Genitourinary Cancers Symposium
FEATURING
Thomas Powles
Login to view comments.
Click here to Login